Gubra A/S

Business Description

Gubra A/S is a Danish biotechnology company founded in 2008 and based in Hørsholm, Denmark, that specializes in peptide-based drug discovery and preclinical research services for clients across Europe, North America, and beyond. The company runs a contract research division offering laboratory and data analysis services to pharmaceutical and biotech firms, alongside an internal pipeline of drug candidates it advances through partnerships and licensing deals. Gubra also holds investments in green transition assets and maintains active collaborations with Boehringer Ingelheim, Camurus, and Amylyx Pharmaceuticals to develop treatments for conditions including obesity, hypoparathyroidism, and post-bariatric hypoglycemia.